{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T14:57:02Z","timestamp":1791212222332,"version":"4.1.0"},"reference-count":112,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T00:00:00Z","timestamp":1222819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2008,10]]},"DOI":"10.1016\/j.prp.2008.07.002","type":"journal-article","created":{"date-parts":[[2008,8,31]],"date-time":"2008-08-31T04:56:23Z","timestamp":1220158583000},"page":"695-706","source":"Crossref","is-referenced-by-count":44,"title":["Mechanisms modulating inflammatory osteolysis: A review with insights into therapeutic targets"],"prefix":"10.1016","volume":"204","author":[{"given":"Shi","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gene P.","family":"Siegal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.prp.2008.07.002_bib1","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1093\/rheumatology\/kel047","article-title":"Gene therapy as a therapeutic approach for the treatment of rheumatoid arthritis: innovative vectors and therapeutic genes","volume":"45","author":"Adriaansen","year":"2006","journal-title":"Rheumatology, Oxford"},{"key":"10.1016\/j.prp.2008.07.002_bib2","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/j.0105-2896.2004.00202.x","article-title":"Is targeting Toll-like receptors and their signaling pathway a useful therapeutic approach to modulating cytokine-driven inflammation?","volume":"202","author":"Andreakos","year":"2004","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.prp.2008.07.002_bib3","first-page":"16","article-title":"The mode of action of cytokine inhibitors","volume":"65","author":"Arend","year":"2002","journal-title":"J. Rheumatol. Suppl."},{"key":"10.1016\/j.prp.2008.07.002_bib4","doi-asserted-by":"crossref","first-page":"13680","DOI":"10.1074\/jbc.M211570200","article-title":"Concomitant recruitment of ERK1\/2 and p38 MAPK signalling pathway is required for activation of cytoplasmic phospholipase A2 via ATP in articular chondrocytes","volume":"278","author":"Berenbaum","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.prp.2008.07.002_bib5","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1002\/j.1460-2075.1996.tb00542.x","article-title":"The p38\/RK mitogen-activated protein kinase pathway regulates interleukin-6 synthesis response to tumor necrosis factor","volume":"15","author":"Beyaert","year":"1996","journal-title":"Embo J."},{"key":"10.1016\/j.prp.2008.07.002_bib6","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1002\/cncr.11138","article-title":"A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases","volume":"97","author":"Body","year":"2003","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.prp.2008.07.002_bib7","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.jbspin.2005.10.019","article-title":"Bisphosphonate therapy in rheumatoid arthritis","volume":"73","author":"Breuil","year":"2006","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.prp.2008.07.002_bib8","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1084\/jem.20022220","article-title":"Impaired differentiation of osteoclasts in TREM-2-deficient individuals","volume":"198","author":"Cella","year":"2003","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.prp.2008.07.002_bib9","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1359\/jbmr.2002.17.2.192","article-title":"In vivo RANK signaling blockade using the receptor activator of NF-kappaB:Fc effectively prevents and ameliorates wear debris-induced osteolysis via osteoclast depletion without inhibiting osteogenesis","volume":"17","author":"Childs","year":"2002","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.prp.2008.07.002_bib10","first-page":"10","article-title":"Interleukin 1 or tumor necrosis factor-alpha: which is the real target in rheumatoid arthritis?","volume":"65","author":"Dayer","year":"2002","journal-title":"J. Rheumatol. Suppl."},{"key":"10.1016\/j.prp.2008.07.002_bib11","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S1359-6101(97)00023-3","article-title":"Interleukin-1","volume":"8","author":"Dinarello","year":"1997","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.prp.2008.07.002_bib12","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1101\/gad.13.18.2412","article-title":"RANK is essential for osteoclast and lymph node development","volume":"13","author":"Dougall","year":"1999","journal-title":"Genes Dev."},{"key":"10.1016\/j.prp.2008.07.002_bib13","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.prp.2008.07.002_bib14","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1517\/13543784.12.4.673","article-title":"The therapeutic potential of costimulatory blockade with CTLA4Ig in rheumatoid arthritis","volume":"12","author":"Emery","year":"2003","journal-title":"Expert Opin. Invest. Drugs"},{"key":"10.1016\/j.prp.2008.07.002_bib15","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/art.21778","article-title":"The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial","volume":"54","author":"Emery","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.prp.2008.07.002_bib16","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1146\/annurev.immunol.19.1.163","article-title":"Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?","volume":"19","author":"Feldmann","year":"2001","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.prp.2008.07.002_bib17","doi-asserted-by":"crossref","first-page":"3482","DOI":"10.1101\/gad.11.24.3482","article-title":"Requirement for NF-kappaB in osteoclast and B-cell development","volume":"11","author":"Franzoso","year":"1997","journal-title":"Genes Dev."},{"key":"10.1016\/j.prp.2008.07.002_bib18","doi-asserted-by":"crossref","first-page":"iii2","DOI":"10.1136\/ard.2006.061937","article-title":"Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006","volume":"65","author":"Furst","year":"2006","journal-title":"Ann Rheum. Dis."},{"key":"10.1016\/j.prp.2008.07.002_bib19","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa050524","article-title":"Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition","volume":"353","author":"Genovese","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.prp.2008.07.002_bib20","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1365-2249.2005.02744.x","article-title":"New therapies for rheumatoid arthritis","volume":"140","author":"Goldblatt","year":"2005","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.prp.2008.07.002_bib21","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1365-2249.2005.02795.x","article-title":"New therapies for systemic lupus erythematosus","volume":"140","author":"Goldblatt","year":"2005","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.prp.2008.07.002_bib22","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1002\/art.1780290704","article-title":"Formation of a synovial-like membrane at the bone\u2013cement interface. Its role in bone resorption and implant loosening after total hip replacement","volume":"29","author":"Goldring","year":"1986","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.prp.2008.07.002_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1902\/jop.2006.77.1.1","article-title":"Effect of topical administration of monosodium olpadronate on experimental periodontitis in rats","volume":"77","author":"Goya","year":"2006","journal-title":"J. Periodontol."},{"key":"10.1016\/j.prp.2008.07.002_bib24","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/1529-0131(200002)43:2<250::AID-ANR3>3.0.CO;2-P","article-title":"Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor","volume":"43","author":"Gravallese","year":"2000","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.prp.2008.07.002_bib25","doi-asserted-by":"crossref","first-page":"ii84","DOI":"10.1136\/ard.61.suppl_2.ii84","article-title":"Bone destruction in arthritis","volume":"61","author":"Gravallese","year":"2002","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.prp.2008.07.002_bib26","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1126\/science.7939685","article-title":"c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling","volume":"266","author":"Grigoriadis","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.prp.2008.07.002_bib27","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1023\/B:CLIN.0000024763.69809.64","article-title":"A small molecule antagonist of the alpha(v)beta3 integrin suppresses MDA-MB-435 skeletal metastasis","volume":"21","author":"Harms","year":"2004","journal-title":"Clin. Exp. Metastasis"},{"key":"10.1016\/j.prp.2008.07.002_bib28","first-page":"46","article-title":"The problem is osteolysis","volume":"311","author":"Harris","year":"1995","journal-title":"Clin. Orthop. Relat. Res."},{"key":"10.1016\/j.prp.2008.07.002_bib29","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S1357-4310(99)01544-0","article-title":"p38 MAPK signaling cascades in inflammatory disease","volume":"5","author":"Herlaar","year":"1999","journal-title":"Mol. Med. Today"},{"key":"10.1016\/j.prp.2008.07.002_bib30","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.bone.2003.08.014","article-title":"Mitf and Tfe3: members of a b-HLH-ZIP transcription factor family essential for osteoclast development and function","volume":"34","author":"Hershey","year":"2004","journal-title":"Bone"},{"key":"10.1016\/j.prp.2008.07.002_bib31","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s001090100226","article-title":"Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology","volume":"79","author":"Hofbauer","year":"2001","journal-title":"J. Mol. Med."},{"key":"10.1016\/j.prp.2008.07.002_bib32","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1101\/gad.1102703","article-title":"Transcriptional regulation by calcium, calcineurin, and NFAT","volume":"17","author":"Hogan","year":"2003","journal-title":"Genes Dev."},{"key":"10.1016\/j.prp.2008.07.002_bib33","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0736-0266(02)00099-2","article-title":"Effect of pamidronate on the stimulation of macrophage TNF-alpha release by ultra-high-molecular-weight polyethylene particles: a role for apoptosis","volume":"21","author":"Huk","year":"2003","journal-title":"J. Orthop. Res."},{"key":"10.1016\/j.prp.2008.07.002_bib34","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1038\/nm1197-1285","article-title":"Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2","volume":"3","author":"Iotsova","year":"1997","journal-title":"Nat. Med."},{"key":"10.1016\/j.prp.2008.07.002_bib35","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1006\/excr.1998.4320","article-title":"Interleukin 1 induces multinucleation and bone-resorbing activity of osteoclasts in the absence of osteoblasts\/stromal cells","volume":"247","author":"Jimi","year":"1999","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.prp.2008.07.002_bib36","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1136\/ard.60.4.305","article-title":"Stem cells for repair of cartilage and bone: the next challenge in osteoarthritis and rheumatoid arthritis","volume":"60","author":"Jorgensen","year":"2001","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.prp.2008.07.002_bib37","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1126\/science.299.5606.495","article-title":"Gene therapy. Seeking the cause of induced leukemias in X-SCID trial","volume":"299","author":"Kaiser","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.prp.2008.07.002_bib38","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1084\/jem.20011681","article-title":"A novel member of the leukocyte receptor complex regulates osteoclast differentiation","volume":"195","author":"Kim","year":"2002","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.prp.2008.07.002_bib39","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1084\/jem.20050978","article-title":"Osteoclast differentiation independent of the TRANCE-RANK-TRAF6 axis","volume":"202","author":"Kim","year":"2005","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.prp.2008.07.002_bib40","doi-asserted-by":"crossref","first-page":"4838","DOI":"10.4049\/jimmunol.173.8.4838","article-title":"Marrow stromal cells and osteoclast precursors differentially contribute to TNF-alpha-induced osteoclastogenesis in vivo","volume":"173","author":"Kitaura","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.prp.2008.07.002_bib41","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1172\/JCI26132","article-title":"M-CSF mediates TNF-induced inflammatory osteolysis","volume":"115","author":"Kitaura","year":"2005","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.prp.2008.07.002_bib42","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1038\/nature02444","article-title":"Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis","volume":"428","author":"Koga","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.prp.2008.07.002_bib43","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/46303","article-title":"Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand","volume":"402","author":"Kong","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.prp.2008.07.002_bib44","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.1002\/art.22134","article-title":"The role of fibroblasts and fibroblast-derived factors in periprosthetic osteolysis","volume":"54","author":"Koreny","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.prp.2008.07.002_bib45","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1002\/1529-0131(200105)44:5<1003::AID-ANR179>3.0.CO;2-#","article-title":"Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients","volume":"44","author":"Kotake","year":"2001","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.prp.2008.07.002_bib46","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1002\/art.21201","article-title":"Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo\u2013controlled trial","volume":"52","author":"Kremer","year":"2005","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.prp.2008.07.002_bib47","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1002\/art.10848","article-title":"Bacterial peptidoglycans but not CpG oligodeoxynucleotides activate synovial fibroblasts by toll-like receptor signaling","volume":"48","author":"Kyburz","year":"2003","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.prp.2008.07.002_bib48","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0092-8674(00)81569-X","article-title":"Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation","volume":"93","author":"Lacey","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.prp.2008.07.002_bib49","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1172\/JCI11176","article-title":"TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand","volume":"106","author":"Lam","year":"2000","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.prp.2008.07.002_bib50","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1359\/jbmr.2001.16.2.319","article-title":"Antagonism of the osteoclast vitronectin receptor with an orally active nonpeptide inhibitor prevents cancellous bone loss in the ovariectomized rat","volume":"16","author":"Lark","year":"2001","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.prp.2008.07.002_bib51","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/S8756-3282(02)00675-0","article-title":"A potent small molecule, nonpeptide inhibitor of cathepsin K (SB 331750) prevents bone matrix resorption in the ovariectomized rat","volume":"30","author":"Lark","year":"2002","journal-title":"Bone"},{"key":"10.1016\/j.prp.2008.07.002_bib52","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/1529-0131(199805)41:5<778::AID-ART4>3.0.CO;2-V","article-title":"Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States","volume":"41","author":"Lawrence","year":"1998","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.prp.2008.07.002_bib53","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/372739a0","article-title":"A protein kinase involved in the regulation of inflammatory cytokine biosynthesis","volume":"372","author":"Lee","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.prp.2008.07.002_bib54","doi-asserted-by":"crossref","first-page":"3524","DOI":"10.1210\/en.2002-221057","article-title":"Interleukin-7 is a direct inhibitor of in vitro osteoclastogenesis","volume":"144","author":"Lee","year":"2003","journal-title":"Endocrinology"},{"key":"10.1016\/j.prp.2008.07.002_bib55","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1210\/en.140.8.3552","article-title":"Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation","volume":"140","author":"Lee","year":"1999","journal-title":"Endocrinology"},{"key":"10.1016\/j.prp.2008.07.002_bib56","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1177\/154405910608500704","article-title":"Inflammation-induced bone remodeling in periodontal disease and the influence of post-menopausal osteoporosis","volume":"85","author":"Lerner","year":"2006","journal-title":"J. Dent. Res."},{"key":"10.1016\/j.prp.2008.07.002_bib57","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1073\/pnas.97.4.1566","article-title":"RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism","volume":"97","author":"Li","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.prp.2008.07.002_bib58","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1002\/art.22033","article-title":"Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate","volume":"54","author":"Maini","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.prp.2008.07.002_bib59","doi-asserted-by":"crossref","first-page":"45969","DOI":"10.1074\/jbc.M408795200","article-title":"Essential role of p38 mitogen-activated protein kinase in cathepsin K gene expression during osteoclastogenesis through association of NFATc1 and PU.1","volume":"279","author":"Matsumoto","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.prp.2008.07.002_bib60","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1056\/NEJMoa044459","article-title":"Denosumab in postmenopausal women with low bone mineral density","volume":"354","author":"McClung","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.prp.2008.07.002_bib61","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1124\/jpet.105.098020","article-title":"A selective p38 alpha mitogen-activated protein kinase inhibitor reverses cartilage and bone destruction in mice with collagen-induced arthritis","volume":"318","author":"Medicherla","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.prp.2008.07.002_bib62","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1093\/oxfordjournals.jbchem.a022231","article-title":"Regulation of interleukin-1beta-induced interleukin-6 gene expression in human fibroblast-like synoviocytes by glucocorticoids","volume":"124","author":"Miyazawa","year":"1998","journal-title":"J. Biochem. (Tokyo)"},{"key":"10.1016\/j.prp.2008.07.002_bib63","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00281-006-0012-9","article-title":"Inhibition of IL-1, IL-6, and TNF-alpha in immune-mediated inflammatory diseases","volume":"27","author":"Moller","year":"2006","journal-title":"Springer Semin. Immunopathol."},{"key":"10.1016\/j.prp.2008.07.002_bib64","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1002\/art.10294","article-title":"Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion","volume":"46","author":"Moreland","year":"2002","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.prp.2008.07.002_bib65","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s10165-006-0501-7","article-title":"Application of cellular gene therapy for rheumatoid arthritis","volume":"16","author":"Nakajima","year":"2006","journal-title":"Mod. Rheumatol."},{"key":"10.1016\/j.prp.2008.07.002_bib66","doi-asserted-by":"crossref","DOI":"10.1136\/ard.2006.068064","article-title":"Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an X-ray reader-blinded randomized controlled trial of tocilizumab","author":"Nishimoto","year":"2007","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.prp.2008.07.002_bib67","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/ncprheum0338","article-title":"Interleukin 6: from bench to bedside","volume":"2","author":"Nishimoto","year":"2006","journal-title":"Nat. Clin. Pract. Rheumatol."},{"key":"10.1016\/j.prp.2008.07.002_bib68","series-title":"The Efficacy of Inhibiting Tumour Necrosis Factor {alpha} and Interleukin 1 in Patients with Rheumatoid Arthritis: A Meta-analysis and Adjusted Indirect Comparisons","author":"Nixon","year":"2007"},{"key":"10.1016\/j.prp.2008.07.002_bib69","doi-asserted-by":"crossref","first-page":"11394","DOI":"10.1073\/pnas.0701971104","article-title":"Pathological role of osteoclast costimulation in arthritis-induced bone loss","volume":"104","author":"Ochi","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.prp.2008.07.002_bib70","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1074\/jbc.M110676200","article-title":"Nonsteroidal anti-inflammatory drugs suppress T-cell activation by inhibiting p38 MAPK induction","volume":"277","author":"Paccani","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.prp.2008.07.002_bib71","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2174\/156802606775270323","article-title":"New approaches to the treatment of inflammatory disorders small molecule inhibitors of p38 MAP kinase","volume":"6","author":"Peifer","year":"2006","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.prp.2008.07.002_bib72","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/S0140-6736(05)67728-8","article-title":"Periodontal diseases","volume":"366","author":"Pihlstrom","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.prp.2008.07.002_bib73","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1359\/jbmr.2000.15.8.1459","article-title":"Fibroblastic stromal cells express receptor activator of NF-kappa B ligand and support osteoclast differentiation","volume":"15","author":"Quinn","year":"2000","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.prp.2008.07.002_bib74","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1089\/10430340152712719","article-title":"A pilot study of in vivo liver-directed gene transfer with an adenoviral vector in partial ornithine transcarbamylase deficiency","volume":"13","author":"Raper","year":"2002","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.prp.2008.07.002_bib75","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ymgme.2003.08.016","article-title":"Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer","volume":"80","author":"Raper","year":"2003","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.prp.2008.07.002_bib76","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1172\/JCI0215582","article-title":"Osteoclasts are essential for TNF-alpha-mediated joint destruction","volume":"110","author":"Redlich","year":"2002","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.prp.2008.07.002_bib77","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1172\/JCI200316069","article-title":"Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis","volume":"111","author":"Ritchlin","year":"2003","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.prp.2008.07.002_bib78","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1038\/sj.gt.3302040","article-title":"Gene therapy for arthritis","volume":"10","author":"Robbins","year":"2003","journal-title":"Gene Ther."},{"key":"10.1016\/j.prp.2008.07.002_bib79","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/S8756-3282(01)00682-2","article-title":"Involvement of receptor activator of NFkappaB ligand and tumor necrosis factor-alpha in bone destruction in rheumatoid arthritis","volume":"30","author":"Romas","year":"2002","journal-title":"Bone"},{"key":"10.1016\/j.prp.2008.07.002_bib80","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1002\/1529-0131(200011)43:11<2501::AID-ANR18>3.0.CO;2-K","article-title":"Activation, differential localization, and regulation of the stress-activated protein kinases, extracellular signal-regulated kinase, c-JUN N-terminal kinase, and p38 mitogen-activated protein kinase, in synovial tissue and cells in rheumatoid arthritis","volume":"43","author":"Schett","year":"2000","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.prp.2008.07.002_bib81","doi-asserted-by":"crossref","first-page":"921","DOI":"10.2174\/1568026054985902","article-title":"The biology of p38 kinase: a central role in inflammation","volume":"5","author":"Schieven","year":"2005","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.prp.2008.07.002_bib82","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/jcb.20659","article-title":"Calmodulin is a critical regulator of osteoclastic differentiation, function, and survival","volume":"97","author":"Seales","year":"2006","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.prp.2008.07.002_bib83","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/S0002-9440(10)63918-1","article-title":"Expression and regulation of Toll-like receptor 2 in rheumatoid arthritis synovium","volume":"162","author":"Seibl","year":"2003","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.prp.2008.07.002_bib84","first-page":"729","article-title":"Novel bone-targeted Src tyrosine kinase inhibitor drug discovery","volume":"6","author":"Shakespeare","year":"2003","journal-title":"Curr. Opin. Drug Discov. Dev."},{"key":"10.1016\/j.prp.2008.07.002_bib85","doi-asserted-by":"crossref","first-page":"15921","DOI":"10.1074\/jbc.M609723200","article-title":"MITF and PU.1 recruit p38 MAPK and NFATc1 to target genes during osteoclast differentiation","volume":"282","author":"Sharma","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.prp.2008.07.002_bib86","first-page":"912","article-title":"Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand\/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells","volume":"63","author":"Shipman","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.prp.2008.07.002_bib87","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s10165-006-0515-1","article-title":"Differences in osteoclast formation between proximal and distal tibial osteoporosis in rats with adjuvant arthritis: inhibitory effects of bisphosphonates on osteoclasts","volume":"16","author":"Shu","year":"2006","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.prp.2008.07.002_bib88","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0092-8674(00)80209-3","article-title":"Osteoprotegerin: a novel secreted protein involved in the regulation of bone density","volume":"89","author":"Simonet","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.prp.2008.07.002_bib89","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(07)60784-3","article-title":"New therapies for treatment of rheumatoid arthritis","author":"Smolen","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.prp.2008.07.002_bib90","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0014-5793(99)01717-2","article-title":"The role of p38 mitogen-activated protein kinase in IL-6 and IL-8 production from the TNF-alpha- or IL-1beta-stimulated rheumatoid synovial fibroblasts","volume":"465","author":"Suzuki","year":"2000","journal-title":"FEBS Lett."},{"key":"10.1016\/j.prp.2008.07.002_bib91","doi-asserted-by":"crossref","first-page":"iii83","DOI":"10.1136\/ard.2006.058388","article-title":"Mitogen activated protein kinase inhibitors: where are we now and where are we going?","volume":"65","author":"Sweeney","year":"2006","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.prp.2008.07.002_bib92","doi-asserted-by":"crossref","first-page":"7422224","DOI":"10.1038\/416744a","article-title":"RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-beta","volume":"416","author":"Takayanagi","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.prp.2008.07.002_bib93","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1126\/science.289.5484.1504","article-title":"Bone resorption by osteoclasts","volume":"289","author":"Teitelbaum","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.prp.2008.07.002_bib94","doi-asserted-by":"crossref","first-page":"427","DOI":"10.2353\/ajpath.2007.060834","article-title":"Osteoclasts: what do they do and how do they do it?","volume":"170","author":"Teitelbaum","year":"2007","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.prp.2008.07.002_bib95","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/nrg1122","article-title":"Genetic regulation of osteoclast development and function","volume":"4","author":"Teitelbaum","year":"2003","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.prp.2008.07.002_bib96","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/386081a0","article-title":"Osteopetrosis in mice lacking haematopoietic transcription factor PU.1","volume":"396","author":"Tondravi","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.prp.2008.07.002_bib97","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1073\/pnas.0136772100","article-title":"IL-7 induces bone loss in vivo by induction of receptor activator of nuclear factor kappa B ligand and tumor necrosis factor alpha from T cells","volume":"100","author":"Toraldo","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.prp.2008.07.002_bib98","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1002\/art.20942","article-title":"The treatment of rheumatoid arthritis: getting better all the time?","volume":"52","author":"van Vollenhoven","year":"2005","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.prp.2008.07.002_bib99","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S0140-6736(06)69210-6","article-title":"Therapeutic efficacy and safety of chaperonin 10 in patients with rheumatoid arthritis: a double-blind randomised trial","volume":"368","author":"Vanags","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.prp.2008.07.002_bib100","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1172\/JCI6145","article-title":"A selective inhibitor of the osteoclastic V-H(+)-ATPase prevents bone loss in both thyroparathyroidectomized and ovariectomized rats","volume":"106","author":"Visentin","year":"2000","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.prp.2008.07.002_bib101","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/med.20042","article-title":"Small molecular anti-cytokine agents","volume":"26","author":"Wagner","year":"2006","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.prp.2008.07.002_bib102","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1210\/en.142.3.1290","article-title":"Receptor activator of nuclear factor-kappa b ligand activates nuclear factor-kappa b in osteoclast precursors","volume":"142","author":"Wei","year":"2001","journal-title":"Endocrinology"},{"key":"10.1016\/j.prp.2008.07.002_bib103","doi-asserted-by":"crossref","first-page":"6622","DOI":"10.1074\/jbc.M104957200","article-title":"Interleukin-4 reversibly inhibits osteoclastogenesis via inhibition of NF-kappa B and mitogen-activated protein kinase signaling","volume":"277","author":"Wei","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.prp.2008.07.002_bib104","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1172\/JCI200523394","article-title":"IL-1 mediates TNF-induced osteoclastogenesis","volume":"115","author":"Wei","year":"2005","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.prp.2008.07.002_bib105","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/PAP.0b013e31802ef4f2","article-title":"p38 MAPK as a potential therapeutic target for inflammatory osteolysis","volume":"14","author":"Wei","year":"2007","journal-title":"Adv. Anat. Pathol."},{"key":"10.1016\/j.prp.2008.07.002_bib106","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1359\/jbmr.2003.18.11.1995","article-title":"Variation in the TNF gene promoter and risk of osteolysis after total hip arthroplasty","volume":"18","author":"Wilkinson","year":"2003","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.prp.2008.07.002_bib107","doi-asserted-by":"crossref","first-page":"4969","DOI":"10.1093\/emboj\/18.18.4969","article-title":"The p38 MAP kinase pathway signals for cytokine-induced mRNA stabilization via MAP kinase-activated protein kinase 2 and an AU-rich region-targeted mechanism","volume":"18","author":"Winzen","year":"1999","journal-title":"Embo J."},{"key":"10.1016\/j.prp.2008.07.002_bib108","doi-asserted-by":"crossref","first-page":"29964","DOI":"10.1074\/jbc.M500710200","article-title":"Fas binding to calmodulin regulates apoptosis in osteoclasts","volume":"280","author":"Wu","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.prp.2008.07.002_bib109","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/345442a0","article-title":"The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene","volume":"345","author":"Yoshida","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.prp.2008.07.002_bib110","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1083\/jcb.200611083","article-title":"Syk, c-Src, the alphavbeta3 integrin, and ITAM immunoreceptors, in concert, regulate osteoclastic bone resorption","volume":"176","author":"Zou","year":"2007","journal-title":"J. Cell. Biol."},{"key":"10.1016\/j.prp.2008.07.002_bib111","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/art.11487","article-title":"Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction","volume":"50","author":"Zwerina","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.prp.2008.07.002_bib112","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/art.21626","article-title":"Activation of p38 MAPK is a key step in tumor necrosis factor-mediated inflammatory bone destruction","volume":"54","author":"Zwerina","year":"2006","journal-title":"Arthritis Rheum."}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033808001635?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033808001635?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,13]],"date-time":"2019-05-13T14:43:20Z","timestamp":1557758600000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0344033808001635"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10]]},"references-count":112,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2008,10]]}},"alternative-id":["S0344033808001635"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2008.07.002","relation":{},"ISSN":["0344-0338"],"issn-type":[{"value":"0344-0338","type":"print"}],"subject":[],"published":{"date-parts":[[2008,10]]}}}